# Post-mortem molecular profiling of three psychiatric disorders

Kevin M. Bowling[1,*], Ph.D., Ryne C. Ramaker[1,2,*], B.S., Brittany N. Lasseigne[1*], Ph.D., Megan H. Hagenauer[3], Ph.D., Andrew A. Hardigan[1,2], B.S., Nick S. Davis[1,#], B.S., Jason Gertz[1,%], Ph.D., Preston M. Cartagena[4], Psy.D., David M. Walsh[4], Psy.D., Marquis P. Vawter[4], Ph.D., Edward G. Jones (deceased), M.D., Ph.D., Alan F. Schatzberg[5], M.D., Jack D. Barchas[6], M.D., Ph.D., Stan J. Watson[3], M.D., Ph.D., Blynn G. Bunney[4], Ph.D., Huda Akil[3], Ph.D., William E. Bunney[4], M.D., Jun Z. Li[7], Ph.D., Sara J. Cooper[1], Ph.D., and Richard M. Myers[1], Ph.D.

*These authors contributed equally to this study

[1]HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA

[2]Department of Genetics, The University of Alabama at Birmingham, Birmingham, AL, USA

[3]Mental Health Research Institute, University of Michigan, Ann Arbor, MI, USA

[4]Department of Psychiatry and Human Behavior, College of Medicine, University of California, Irvine, Irvine, CA, USA

[5]Department of Psychiatry, Stanford University School of Medicine, Stanford, CA, USA

[6]Psychiatry, Weill Cornell Medical College, New York, NY, USA

[7]Department of Human Genetics, University of Michigan, Ann Arbor, MI, USA

Present address:

[#]Duke University, Durham, NC, USA

[%]University of Utah School of Medicine, Salt Lake City, UT, USA

To whom correspondence should be addressed:

Richard M. Myers, Ph.D.

HudsonAlpha Institute for Biotechnology

601 Genome Way

Huntsville, AL 35806

Telephone: 256-327-0431

FAX: 256-327-0978

rmyers@hudsonalpha.org

# Abstract

## Background

Psychiatric disorders are multigenic diseases with complex etiology contributing significantly to human morbidity and mortality. Although clinically distinct, several disorders share many symptoms suggesting common underlying molecular changes exist that may implicate important regulators of pathogenesis and new therapeutic targets.

## Results

We compared molecular signatures across brain regions and disorders in the transcriptomes of postmortem human brain samples. We performed RNA sequencing on tissue from the anterior cingulate cortex, dorsolateral prefrontal cortex, and nucleus accumbens from three groups of 24 patients each diagnosed with schizophrenia, bipolar disorder, or major depressive disorder, and from 24 control subjects, and validated the results in an independent cohort. The most significant disease differences were in the anterior cingulate cortex of schizophrenia samples compared to controls. Transcriptional changes were assessed in an independent cohort, revealing the transcription factor *EGR1* as significantly down regulated in both cohorts and as a potential regulator of broader transcription changes observed in schizophrenia patients. Additionally, broad down regulation of genes specific to neurons and concordant up regulation of genes specific to astrocytes was observed in SZ and BPD patients relative to controls. We also assessed the biochemical consequences of gene expression changes with untargeted metabolomic profiling and identified disruption of GABA levels in schizophrenia patients.

**Conclusions**

We provide a comprehensive post-mortem transcriptome profile of three psychiatric disorders across three brain regions. We highlight a high-confidence set of independently validated genes differentially expressed between schizophrenia and control patients in the anterior cingulate cortex and integrate transcriptional changes with untargeted metabolite profiling.

## Keywords

Schizophrenia, Bipolar Disorder, Major Depressive Disorder, RNA sequencing, metabolomics, *EGR1*

## Background

Schizophrenia (SZ), bipolar disorder (BPD), and major depressive disorder (MDD) are multigenic diseases with complex etiology and are large sources of morbidity and mortality in the population. All three disorders are associated with high rates of suicide, with ~90% of the ~41,000 people who commit suicide each year in the U.S. having a diagnosable psychiatric disorder [2]. Notably, while clinically distinct, these disorders also share many symptoms, including psychosis, suicidal ideation, sleep disturbances and cognitive deficits [3–5]. This phenotypic overlap suggests potential common genetic etiology, which is supported by recent large-scale genome-wide association studies [6–9]. However, this overlap has not been fully characterized with functional genomic approaches. Current therapies for these psychiatric disorders are ineffective in many patients and often only treat a subset of an individual patient's symptoms [10]. Approaches targeting the underlying molecular pathologies within and across these

types of disorders are necessary to address the immense burden of psychiatric disease around the world and improve care for the millions of people diagnosed with these conditions.

Previous studies [11–15] analyzed brain tissue with RNA sequencing (RNA-seq) in SZ and BPD, and identified altered expression of GABA-related genes in the superior temporal gyrus and hippocampus, as well as differentially expressed genes related to neuroplasticity and mammalian circadian rhythms. Our study focused on the anterior cingulate cortex (AnCg), dorsolateral prefrontal cortex (DLPFC), and nucleus accumbens (nAcc), regions which are often associated with mood alterations, cognition, impulse control, motivation, reward, and pleasure – all behaviors known to be altered in psychiatric disorders [16,17]. To assess gene expression changes associated with psychiatric disease in these three brain regions, we performed RNA-seq on macro-dissected post-mortem tissues in four well-documented cohorts of 24 patients each with SZ, BPD, MDD and 24 controls (CTL) (96 individuals total). Additionally, we conducted metabolomic profiling of AnCg tissue from the same subjects. RNA-seq analysis revealed common expression profiles in SZ and BPD patients supporting the notion that these disorders share a common molecular etiology. Transcriptional changes were most pronounced in the AnCg with SZ and BPD exhibiting strongly correlated differences from CTL samples. Differentially expressed genes were associated with cell-type composition with BPD and SZ samples showing decreased expression of neuron-specific transcripts. We validated this result with RNA-seq data from an independent cohort of 35 cases each of SZ, BPD, and CTL post-mortem cingulate cortex samples from the Stanley Neuropathology Consortium Integrative Database (SNCID;

http://sncid.stanleyresearch.org) Array Collection. We present a set of validated genes differentially expressed between SZ and CTL patients, perform an integrated analysis of metabolic pathway disruptions, and highlight a role for the transcription factor, *EGR1*, whose down-regulation in SZ patients may drive a large portion of observed transcription changes.

## Methods

See Supplemental Methods for additional detail.

### Patient Sample Collection and Preparation

Sample collection, including human subject recruitment and characterization, tissue dissection, and RNA extraction, was described previously [18,19] as part of the Brain Donor Program at the University of California, Irvine, Department of Psychiatry and Human Behavior (Pritzker Neuropsychiatric Disorders Research Consortium) under IRB approval. In brief, coronal slices of the brain were rapidly frozen on aluminum plates that were pre-frozen to -120$^{o}$C and dissected as described previously [20]. All samples were diagnosed by psychological autopsy, which included collection and analyses of medical and psychiatric records, toxicology, medical examiners' reports, and 141-item family interviews. Agonal state scores were assigned based on a previously published scale [21]. Controls were selected based upon absence of severe psychiatric disturbance and mental illness within first-degree relatives.

We obtained fastq files from RNA-seq experiments for our validation cohort from the Stanley Neuropathology Consortium Integrative Database (SNCID; http://sncid.stanleyresearch.org) Array Collection comprising 35 cases each of SZ, BPD,

and CTL of post-mortem cingulate cortex with permission on June 30, 2015. For our analysis, we included the 27 SZ, 26 CTL, and 25 BPD SNCID samples that were successfully downloaded and represented unique samples. SNCID RNA-seq methodology and data processing is described in detail in a previous publication that makes use of the data [11].

**RNA-seq and Data Processing**

To extract nucleic acid, 20 mg of post-mortem brain tissue was homogenized in Qiagen RLT buffer + 1% BME using an MP FastPrep-24 and Lysing Matrix D beads for three rounds of 45 seconds at 6.5 m/s (FastPrep homogenizer, lysing matrix D, MP Bio). Total RNA was isolated from 350 µL tissue homogenate using the Norgen Animal Tissue RNA Purification Kit (Norgen Biotek Corporation). We made RNA-seq libraries from 250 ng total RNA using polyA selection (Dynabeads mRNA DIRECT kit, Life Technologies) and transposase-based non-stranded library construction (Tn-RNA-seq) as described previously [22]. To mitigate potentially confounding batch affects in sample preparation we randomly assigned samples from all brain regions and disorders into batches of 24 samples. We used KAPA to quantitate the library concentrations and pooled 4 samples in order to achieve equal concentration of the four libraries in each lane. Pools were determined by random from the 291 samples. Samples were also randomly selected for pooling in an effort to limit potentially confounding sequencing batch effects. The pooled libraries were sequenced on an Illumina HiSeq 2000 sequencing machine using paired-end 50 bp reads and a 6 bp index read, resulting in an average of 48.2 million reads per library. To quantify the expression of each gene in both Pritzker and SNCID datasets, RNA-seq reads were processed with aRNApipe v1.1 using default settings [23]. Briefly,

reads were aligned and counted with STAR v2.4.2a to GRCh37_E75 [24]. All alignment quality metrics were obtained from the picard tools module (http://broadinstitute.github.io/picard/) available in aRNApipe. Transcripts expressed from the X and Y chromosomes were omitted from the study.

Quantitative PCR (qPCR) was performed on 10 SZ and 10 CTL patients to validate *EGR1* RNA-seq measurements. RNA was extracted as described above from tissue lysates a second time. Reverse transcription was performed on 250ng of input RNA with the Applied Biosystems high capacity cDNA reverse transcription kit. Validated Taqman assays for EGR1 (Hs00152928_m1) and the housekeeper genes GAPDH (Hs02758991_g1) and ACTB (Hs01060665_g1) were used for qPCR. cDNA was diluted by a factor of 10 before use as input for the Taqman assay. The qPCR reaction was performed on an Applied Biosystems Quant Studio 6 Flex system using the recommended amplification protocol for Taqman assays.

**Sequencing Data Analysis**

All data analysis in R was performed with version 3.1.2.

*Differential Expression Analysis and Normalization*

To examine gene expression changes, we employed the R package DESeq2 [1] (version 1.6.3), using default settings, but employing likelihood ratio test (LRT) hypothesis testing, and removing non-convergent transcripts from subsequent analysis. Genes differentially expressed between each disorder and CTL samples, by brain region, were identified with DESeq2 (adjusted p-value<0.05), including age, brain pH, PMI, and percentage of reads uniquely aligned (PRUA) as covariates (Full Model:

~Age+PMI+pH+PRUA+Disorder, Reduced Model: ~ Age+PMI+pH+PRUA). For downstream heatmap visualization, PCA, and cell-type analysis, transcripts were underwent a log-like normalization using DESeq2's varianceStabilizingTransformation function and were corrected for PRUA by computing residuals to a linear model regressing PRUA on normalized transcript amount with the R lm function unless otherwise specified.

*PCA and Hierarchical Clustering*

PCA analysis was performed in R on normalized data using the prcomp() command. Hierarchical clustering of normalized transcript data was done in R with the hclust command (method="ward", distance="Euclidean")

*Pathway Enrichment Analysis*

Pathway analysis was conducted using the web-based tool LRPath [25] using all GO term annotations, adjusting to transcript read count with RNA-Enrich, including directionality and limiting maximum GO term size to 500 genes. GO term visualization was performed using the Cytoscape Enrichment Map plug-in [26]. The Genesetfile (.gmt) GO annotations from February 1, 2017 were downloaded from http://download.baderlab.org/EM_Genesets/. The LRPath output was parsed and used as an enrichment file with all upregulated pathways colored red and all downregulated pathways colored blue, regardless of degree of upregulation. Mapping parameters were; p-value cutoff = 0.005, FDR cutoff = 0.1 and Jaccard coefficient > 0.3. Resulting networks were exported as PDFs. Summary terms were added to the plot based on the GO terms in those clusters. In order to assess overlap between significant GO terms and our analysis and the GWAS study described by the Psychiatric Genomics

Consortium, we downloaded the p-values reported for Schizophrenia hits from Supplemental Table 4, which contained 424 significant GO terms. We used a chi-squared test to assess significant overlap between the two groups. Supplemental Table X reports the p-values measured in SZ based on this study along with those calculated in our analysis.

*EGR1 ChIP-seq peak analysis*

Narrow peak bed files from optimal IDR thresholded peaks were obtained from the ENCODE data portal (www.encodeproject.org) for *EGR1* ChIP-seq data in GM12878, H1-hESC, and K562 cell lines (ENCODE file IDs: ENCFF002CIV, ENCFF002CGW, ENCFF002CLV). Consensus *EGR1* peaks were identified by intersecting peaks from all three cell lines, which resulted in a final list of 4,121 peaks that were present in each cell line (with a minimum overlap of 1bp). The distance from each annotated transcription start site (TSS) to the nearest consensus *EGR1* peak was computed using TSSs annotated in the ENSEMBL gene transfer format (GTF) file used for aligning RNA-seq reads (GRCh37_E75).

*Cell-Specific Enrichment Analysis*

Sets of transcripts uniquely expressed by several brain cell-types were obtained from figure 1B in Darmanis et. al [27]. An index for each cell-type was created by finding the median normalized expression value for each cell-type associated transcript set. Index values were compared across patient clusters by non-parametric rank sum tests and spearman correlation with top principal components. To validate our method, we calculated cell-type specific indices from an independent cohort of previously published purified brain cells [28,29]. FPKM-normalized transcript data was obtained from

supplemental table 4 of Zhang et. al. (2014) and cell-type indexes were calculated as described above. To examine index performance in mixed cell populations, we obtained fastq files for neuron and astrocyte-purified brain samples from GEO accession GSE73721 and generated raw count files as described above. We next mixed expression profiles *in silico* by performing random down-sampling of neuron and astrocyte count levels and summing the results such that mixed populations containing specific proportions of counts from neuron- and astrocyte-purified tissue were generated. For example, to generate an 80/20 neuron to astrocyte mixture, neuron and astrocyte count columns (which started at an equivalent number of 5,759,178 aligned reads) were randomly down-sampled to 4,607,342 and 1,151,836 counts respectively and summed across each gene to result in a proportionately mixed population of aligned count data simulating heterogeneous tissue. Then we calculated a neuron/astrocyte index ratio capable of predicting the *in silico* mixing weights. Briefly, we assumed index values for mixed cell populations were directly proportional to mixing weights of their respective purified tissue, thus the predicted cell proportion for a given cell type was simply calculated as:

$$\text{predicted cell proportion} = \text{observed index value}/\text{purified tissue index value}$$

To insure cell-type predictive power was unique to indices derived from Darmanis et. al transcripts, we generated indices from 10,000 randomly sampled transcript sets of equivalent size and examined their performance in predicting *in silico* mixing weights. Mean squared prediction errors (MSE) were calculated for each of the 10,000 null indices and compared to the MSE of Darmanis et. al.-derived indices.

**Metabolomics**

*Sample preparation*

Sections of approximately 100mg of frozen tissue were weighed and homogenized for 45 seconds at 6.5M/s with ceramic beads in 1mL of 50% methanol using the MP FastPrep-24 homogenizer (MP Biomedicals). A sample volume equivalent to 10mg of initial tissue weight was dried down at 55$^{o}$C for 60 minutes using a vacuum concentrator system (Labconco). Derivatization by methoximation and trimethylsilylation was done as previously described [30].

We analyzed technical replicates of each tissue sample, in randomized order.

*GCxGC-TOFMS analysis*

All derivatized samples were analyzed on a Leco Pegasus 4D system (GCxGC-TOFMS), controlled by the ChromaTof software (Leco, St. Joseph, MI). Samples were analyzed as described previously [30] with minor modifications in temperature ramp.

*Data analysis and metabolite identification*

Peak calling, deconvolution and library spectral matching were done using ChromaTOF 4.5 software. Peaks were identified by spectral match using the NIST, GOLM [31], and Fiehn libraries (Leco), and confirmed by running derivatized standards (Sigma). We used Guineu for multiple sample alignment [32].

*Integrated Pathway Analysis*

Altered metabolites and transcripts were analyzed for enrichment in KEGG pathways containing both metabolite and gene features. A non-parametric, threshold free pathway analysis similar to that of a previously described method [33] was first performed on metabolite and transcript data separately. Our method builds on the principle described

by Subramanian that implements a one-tailed Wilcox test to identify pathways enriched for low p-values. Instead of just accounting for enrichment at the gene level, we use metabolite or transcript p-value ranks within each pathway compared to remaining non-pathway metabolites or transcripts with a one-tailed Wilcox test to test the hypothesis that elements of a given pathway may be enriched for lower p-value ranks than background elements. Metabolite and transcript p-values were subsequently combined to provide an integrated enrichment significance p-value using Fisher's method. Pathways had to contain greater than 5 genes and 1 metabolite measured in our dataset to be included in the analysis. Supplemental table 10 lists p-values for enriched pathways based on genes, metabolites or combined.

## Results

### Region-specific gene expression in control and psychiatric brain tissue

We collected post-mortem human brain tissue, associated clinical data, including age, sex, brain pH, and post-mortem interval (PMI), and cytotoxicology results (Tables S1-2) for matched cohorts of 24 patients each diagnosed with SZ, BPD, or MDD, as well as 24 control individuals with no personal history of, or first-degree relatives diagnosed with, psychiatric disorders. Importantly, to limit the effect of acute patient stress at the time of death as a potential confounder we included only patients with an agonal factor score of zero and a minimum brain pH of 6.5 [19]. Using RNA-seq [22], we profiled gene expression in three macro-dissected brain regions (AnCg, DLPFC, nAcc). After quality control, we analyzed 57,905 ENSEMBL transcripts in a total of 281 brain samples (Table S3).

To examine heterogeneity across brain regions and subjects, we performed a principal component analysis (PCA; Figure S1A) of all transcripts. The first principal component (PC1, 21.8% of the variation) separates cortical AnCg and DLPFC samples from subcortical nAcc samples. Examination of the first and second principal components for disorder associations reveals a separation of some SZ and BPD samples from all other samples (Figures S1B and S2A-C). However, in agreement with several previously reported post-mortem brain RNA sequencing studies [15], we found several principal components to be highly correlated with quality metrics including the percentage of reads uniquely aligned and percentage of reads aligned to mitochondrial sequence (absolute Rho>0.5, FDR<1E-16, Table S4). To reduce the potentially confounding effects of sample quality, we repeated the PCA on expression data normalized to the percentage of reads uniquely aligned for each sample and found that global disease-specific expression differences were significantly reduced (Figures S1C and S2D-I).

**Disease-specific gene expression in control and psychiatric brains**

We next applied DESeq2 [1], a method for differential analysis of sequence read count data, to identify genes differentially expressed across disorders within each brain region after correcting for biological and technical covariates. The largest number of significant expression changes occurred in AnCg between SZ and CTL individuals (87 transcripts, FDR<0.05, Figure 1A). Pathway enrichment analysis of differentially expressed genes between SZ and CTL patients revealed 935 gene ontology (GO) terms with an FDR<0.05 (Table S5) (122 GOCC, 159 GOMF, and. 654 GOBP). Significant GO terms fall into the broad categories of synaptic function and signaling (e.g. neurotransmitter transport, ion transport, calcium signaling) (Figure S3). These terms overlap significantly

with those identified by the Psychiatric Genomics Consortium in their analysis of GWAS implicated genes [34] with 68 GO terms meeting a p-value cutoff of <0.05 in both datasets (p<0.0001, Chi-square test). Additionally, nine genes were differentially expressed between SZ and CTL individuals in DLPFC. Three of these were also identified in AnCg: *SST*, *PDPK2P* and *KLHL14*. No transcripts had an FDR<0.05 when comparing BPD or MDD samples to CTLs in any brain region, or comparing SZ and CTL tissues in nAcc (Table S6). To examine potential common gene expression patterns between the psychiatric disorders, we performed pair-wise correlation calculations of all transcript $\log_2$ fold changes for each disorder versus controls in each brain region. Of the nine case-control comparisons (for three regions and three diseases), a particularly strong correlation is observed between BPD and SZ compared to either SZ or BPD and MDD in each brain region (Figure 1B). In the AnCg, BPD and SZ share 1,020 common genes differentially expressed at an uncorrected DESeq2 *P*-value<0.05 compared to only 248 and 143 genes shared between MDD and SZ or BPD respectively (Figure 1C). This strong overlap between BPD and SZ (Fisher's exact p-value<1E-16) indicates that although expression changes are weaker in BPD they follow a trend similar to those identified in SZ.

Because previous post-mortem analyses have been limited by, and are particularly vulnerable to, biases inherent to examining a single patient cohort, we sought to generate a robust set of SZ associated transcripts by validating our observed expression changes in an independent cohort. To accomplish this, we examined gene expression differences in the AnCg between SZ and CTL samples in the SNCID RNA-seq Array dataset [14], revealing 1,003 genes differentially regulated (DESeq2

uncorrected *P*<0.05) in both datasets (Fisher's *P*<1E-16, Table S7). The magnitude and direction of change in significant transcripts in the Pritzker dataset were highly correlated with the SNCID dataset (Rho=0.202, *P*<1E-16), particularly in transcripts that met an FDR<0.05 cutoff (Rho=0.812, P<1E-16; Figure 1D). We performed hierarchical clustering of SZ and CTL samples in the SNCID validation cohort using the 1,003 transcripts differentially expressed between SZ and CTL in the Pritzker dataset (*P*<0.05, Figure 1E), and found these transcripts successfully distinguished the two disease groups with only 5 out of 27 SZ and 2 out of 26 CTL samples misclassified.

Of particular interest are a group of 5 genes significant at a FDR<0.05 in both cohorts that includes a nearly 2-fold decrease in expression of the transcription factor *EGR1* (Table S7A, Figure 2A). Quantitative PCR (qPCR) validation of the transcript confirmed reduced EGR1 expression in SZ samples (Figure 2B). *EGR1*, a zinc finger transcription factor, has been recently implicated in SZ by a GWAS study [6], thus we sought to investigate its role as a potential driver of the transcriptional changes observed in the AnCg of SZ patients using publicly available genome-wide occupancy data from the ENCODE consortium (https://www.encodeproject.org). To obtain high confidence *EGR1* binding sites we intersected chromatin immunoprecipitation sequencing (ChIP-Seq) peaks derived from the H1-hESC, K562, and GM12878 cell lines. We found that transcripts whose transcription start sites (TSSs) were within 1kb of an EGR1 binding site had significantly lower DESeq2 *P*-values (Wilcox *P*=9.68E-5) and significantly more negative log2 fold changes (SZ/CTL, Wilcox *P*=7.69E-15) than transcripts whose TSSs were greater than 1kb from an *EGR1* binding site. A monotonic decrease in this effect

was observed as the distance threshold used for this comparison was increased from 1kb to 50kb (Figure 2C).

**Cell type specific changes**

In addition to dysregulation of broadly acting transcription factors, another mechanism that can drive large-scale transcriptional changes in bulk tissue is alterations in constituent cell type proportions. Previous studies have observed decreases in neuron density and increased glial scarring in psychiatric disorders [35,36]. To test for signs of these alterations in our data set we examined the expression of cell type-specific transcripts identified using data from a single cell RNA sequencing study that identified transcripts capable of classifying individual cells into the major neuronal, glial, and vascular cell-types in the brain. We generated cell type indices using the median of normalized counts for each cell type-specific transcript set. Examining cell type indices in a previously published RNA-seq analysis of purified brain cells reveals high specificity of each index to the appropriate cell type and accurate deconvolution of transcriptomes mixed *in silico* [29,28] (Figure S4A-F). Moreover, median values from 10,000 randomly sampled transcript sets are not able to deconvolute mixed cell transcriptomes, demonstrating that predictive power is relatively unique to the Darmanis et al. transcript sets (Figure S4G-I).

Application of the cell type indices to patient AnCg expression data revealed a significant decrease in neuron specific expression (Wilcox $P<0.05$) and a significant increase in astrocyte specific expression (Wilcox $P<0.05$) in SZ and BPD patients compared to controls (Figures 3A-B). Other cell-type indices were not significantly different between psychiatric patients and controls (Figure S5). Further supporting a

decrease in neuronal gene expression, we found a significant negative correlation between transcript expression in patient brains relative to control brains and the degree of neuron specificity (fold enrichment of neuron expression over other cell types) in SZ and BPD (rho -0.50 and -0.41, *P*<1E-16, SZ shown in Figure 3C).

**Transcriptomic changes reflected in altered metabolomic profiles**

To assess the biochemical consequences of expression changes, we used 2D-GCMS to measure metabolite levels in 86 of the AnCg samples (sufficient tissue was unavailable for 10 samples). We measured and identified 141 unique metabolites (Table S8). Similar to our transcript analysis, metabolite levels (Table S9) successfully differentiated SZ and BPD patients from CTLs (Figures 4A-B), while MDD metabolite profiles were very similar to CTLs (Figure S6). Several of the most significant metabolites, including GABA, are known to be relevant to BPD and SZ [37]. Furthermore, GABA/glutamate metabolite ratios correlate strongly with average *GAD1* and *GAD2* expression levels (Rho = 0.413, *P*=0.007, Figures 4C-D). This metabolite-gene relationship is consistent with previous multi-level phenomic analyses [38] and demonstrates realized biochemical consequences from altered gene expression. Notably, reductions in GABA could coincide with loss of neurons suggested by the gene expression data. Integrated pathway analyses of KEGG pathways enriched for both altered metabolites and transcripts between SZ and CTL patients revealed disruption of synaptic and neurotransmitter signaling (Figure S7, Table S10).

## Discussion

Here, we describe a large transcriptomic dataset across three brain regions (DLPFC, AnCg, and nAcc) in SZ, BPD, and MDD patients, as well as CTL samples matched for agonal state and brain pH. In MDD, we do not identify any transcripts that meet genome-wide significance for differential expression between cases and controls in any brain region. This finding agrees with previous post-mortem RNA-seq studies [39], however sample size and the choice of brain regions examined likely contributed to our inability to replicate results from previous non-transcriptome wide sequencing based approaches comparing MDD to CTL in post-mortem brain [40]. One limitation of our study is that females are underrepresented at a rate of about 5:1. This reflects the increased chance of accidental death among males [41], but limits us in our ability to make more general conclusions about these disorders and to address known differences between the sexes as they relate to these disorders. We also do not have information on the smoking status for our cohort, which is an important covariate as smoking rates are higher among patients with psychiatric disorders and smoking has been demonstrated to effect gene expression [42,43]. Another potential limitation inherent to post-mortem cohort analyses is accounting for patient drug use. As detailed in supplemental table 2, patient toxicology reports were positive for several prescribed and illicit drugs that were not present in CTL samples. As this is a bias inherent to psychiatric patients it is impossible to disentangle from non-treatment related disease patterns in a post-mortem analysis.

Another important limitation of post-mortem RNA-sequencing studies is RNA quality. We found a significant proportion of variation in our data to be associated with multiple alignment quality metrics. Significant effort went into controlling for potential sources of

bias due to differences in RNA quality. We only included tissue from patients with an agonal score of 0 and who had a brain pH of 6.5 or greater. We also controlled for brain pH, post-mortem interval, and alignment quality in all differential expression analyses. Our study, as well as future post-mortem studies, could be improved by directly measuring RNA quality at the time of sample preparation (e.g. RNA integrity number (RIN)). Despite these caveats, we believe our data do yield new insights that contribute to our growing understanding of these disorders.

The most dramatic gene expression signals we observed were brain region-specific. The majority of disease-associated expression differences were seen in the AnCg of SZ compared to CTL patients. The AnCg has been associated with multiple disease-relevant functions, including cognition, error detection, conflict resolution, motivation, and modulation of emotion [44–46]. We observed a striking overlap in SZ- and BPD-associated expression changes consistent with previous findings [37,47].

One of the more intriguing transcripts significantly down regulated (FDR<0.05) in both cohorts of SZ patients was the zinc finger transcription factor, *EGR1*. We provide evidence that this factor may be driving a large proportion of variation in SZ patients as transcripts near consensus *EGR1* binding sites tend to have decreased expression in SZ patients. Down regulation of *EGR1* has been previously described in the prefrontal cortex of post-mortem brain samples from SZ patients [48,49]. *EGR1* has also previously been associated with several phenotypes relevant to psychiatric disorder including neural differentiation [50], emotional memory formation [51], response to antipsychotics [52], and has recently been described as part of a transcription factor-miRNA co-regulatory network capable of acting as a biomarker in peripheral blood cells

(PBCs) for SZ [53]. In mice, loss of *EGR1* has linked to neuronal loss in a model of Alzheimer's Disease [54]. EGR1 is also important for regulation of the NMDA Receptor pathway, which is critical for synaptic plasticity and memory formation and has been implicated in SZ in humans [55]. We believe a more detailed examination of genome-wide *EGR1* occupancy in post-mortem brain tissue or cultured neurons could yield additional information and assessment of the functional consequences of *EGR1* perturbation is required to confirm this factor's role in SZ pathogenesis.

We also see evidence for depletion of neuron-specific transcripts and increased levels of astrocyte-specific transcripts in SZ and BPD patients. This observation is further supported by metabolomic analysis of the AnCg, which found a concordant decrease in GABA levels in BPD and SZ individuals. Neuronal depletion has been previously described in SZ [35,36]. Insufficient tissue remains from our patient cohort to validate computational cell type predictions immunohistochemically, however our data strongly suggests that future post-mortem studies should be cognizant of cell type heterogeneity across patient samples. The method for cell type composition estimation is limited in its accuracy to estimating only the major classes of cells present. Transcripts represented in cell types present at only a small minority could be over or under-represented using this technique. Based on these results, future studies should consider using robust techniques for assessing tissue composition to examine potential cell type proportion differences between disease cohorts and to identify which transcriptional changes occur in conjunction with, and independent of, those differences.

We observed greatly reduced or no significant expression differences in the DLPFC and nAcc, which contradicts several previous studies [56,57]. We do not intend to claim that

no transcriptional changes occur in these brain regions as our study was designed to broadly compare transcriptional alterations across multiple brain regions in multiple psychiatric disorders, thereby sacrificing exceptional sample sizes in any single disorder in any specific brain region. However, our data does suggest that of the regions we tested, the strongest transcriptional changes occur in the AnCg of SZ patients. Moreover, this data provides a useful resource for future studies facilitating the testing of preliminary hypotheses or validation of significant findings.

## Conclusions

Our study provides several meaningful and novel contributions to the understanding of psychiatric disease. We provide a well-annotated data set that has the potential to act as a broadly applicable resource to investigators interested in molecular changes in multiple psychiatric disorders across multiple brain regions. We have conducted an extensive characterization of the molecular overlap between SZ and BPD at the transcript and metabolite level across multiple brain regions. We provide a high confidence set of genes differentially expressed between SZ and CTL patients utilizing two independent cohorts and highlight down regulation of *EGR1* as a potential driver of broader scale transcription changes. We also establish that a significant proportion of transcriptome variation within SZ and BPD cohorts is correlated with expression changes in previously identified cell type-specific transcripts.

## List of abbreviations

RNA-seq – RNA sequencing

GABA – gamma-Aminobutyric acid

GWAS – genome-wide association study

SZ – schizophrenia

BPD – bipolar disorder

MDD – major depression disorder

CTL – control

AnCg – anterior cingulate gyrus

DLPFC – dorsolateral prefrontal cortex

nAcc – nucleus accumbens

GO – gene ontology

ChIP-seq – chromatin immunoprecipitation with DNA sequencing

PCA – principal component analysis

## Declarations

### Ethics approval and consent to participate

Sample collection, including human subject recruitment and characterization, was conducted as part of the Brain Donor Program at the University of California, Irvine, Department of Psychiatry and Human Behavior (Pritzker Neuropsychiatric Disorders Research Consortium) under IRB approval (UCI 88-041, UCI 97-74).

### Consent for publication

Not applicable

### Availability of data and materials

The datasets supporting the conclusions of this article are available in the GEO repository, GSE80655.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

The Pritzker Neuropsychiatric Disorders Research Fund L.L.C. and the NIH-National Institute of General Medical Sciences Medical Scientist Training Program (5T32GM008361-21) supported this work.

**Author's Contributions**

HA, SJW, AFS, WEB, JDB, HK, SJC and RMM conceived of study

KMB, RCR, BNL, SJC, AAH, MH, JZL and RMM designed the experiments

EGJ performed brain dissections

PMC procured the brain tissue samples

MPV analyzed pH on all cases and matched the 4 cohorts

DWM obtained demographic and clinical data on all subjects through analyses of medical records and next-of-kin interviews

NSD, JG, and KMB collected RNAs and performed Tn-RNA-seq library construction

RCR and BNL analyzed the RNA-seq data

RCR and SJC performed and analyzed metabolomics experiments

KMB, RCR, and BNL wrote the first draft of the paper

JZL, BGB, WEB, SJW, SJC, HA and RMM contributed to the writing of the paper

All authors read and approved the final manuscript.

**Acknowledgements**

We thank Marie Kirby, Brian Roberts, Mark Mackiewicz, and Greg Cooper for many helpful discussions and comments on the manuscript, and all the members of the Pritzker Neuropsychiatric Disorders Consortium for their support and advice.

## References

1. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. [Internet]. 2014 [cited 2014 Dec 23];15:550. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4302049&tool=pmcentrez&rendertype=abstract

2. CDC Burden of Mental Illness. 2015.

3. DSM-5. Diagnostic and Statistical Manual. 2013.

4. Caldwell CB, Gottesman II. Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophr. Bull. 1990;16:571–89.

5. Siris SG. Suicide and schizophrenia. J. Psychopharmacol. [Internet]. 2001 [cited 2017 Feb 16];15:127–35. Available from: http://jop.sagepub.com/cgi/doi/10.1177/026988110101500209

6. Ripke S, Neale BM, Corvin A, Walters JTR, Farh K-H, Holmans P a., et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature [Internet].

2014;511:421–7. Available from: http://www.nature.com/doifinder/10.1038/nature13595

7. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460:748–52.

8. Cross-disorder Psychiatric Genomics Group. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet [Internet]. 2013 [cited 2014 Jan 20];381:1371–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23453885

9. Lee SH, Ripke S, Neale BM, Faraone S V, Purcell SM, Perlis RH, et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat. Genet. [Internet]. 2013 [cited 2014 Jan 21];45:984–94. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23933821

10. Jääskeläinen E, Juola P, Hirvonen N, McGrath JJ, Saha S, Isohanni M, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr. Bull. 2013;39:1296–306.

11. Hwang Y, Kim J, Shin JY, Kim JI, Seo JS, Webster MJ, et al. Gene expression profiling by mRNA sequencing reveals increased expression of immune/inflammation-related genes in the hippocampus of individuals with schizophrenia. Transl. Psychiatry. 2013;3:e321.

12. Kohen R, Dobra A, Tracy JH, Haugen E. Transcriptome profiling of human hippocampus dentate gyrus granule cells in mental illness. Transl. Psychiatry. 2014;4:e366.

13. Akula N, Barb J, Jiang X, Wendland JR, Choi KH, Sen SK, et al. RNA-sequencing of the brain transcriptome implicates dysregulation of neuroplasticity, circadian rhythms and GTPase binding in bipolar disorder. Mol. Psychiatry [Internet]. 2014 [cited 2015 May 27];19:1179–85. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24393808

14. Darby MM, Yolken RH, Sabunciyan S. Consistently altered expression of gene sets in postmortem brains of individuals with major psychiatric disorders. Transl. Psychiatry [Internet]. 2016 [cited 2016 Oct 7];6:e890. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27622934

15. Fromer M, Roussos P, Sieberts SK, Johnson JS, Kavanagh DH, Perumal TM, et al. Gene expression elucidates functional impact of polygenic risk for schizophrenia. Nat. Neurosci. [Internet]. 2016 [cited 2016 Oct 7]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/27668389

16. Olsen CM. Natural rewards, neuroplasticity, and non-drug addictions. Neuropharmacology [Internet]. 2011 [cited 2015 Jun 17];61:1109–22. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3139704&tool=pmcentrez&rendertype=abstract

17. Wenzel JM, Rauscher NA, Cheer JF, Oleson EB. A role for phasic dopamine release within the nucleus accumbens in encoding aversion: a review of the neurochemical literature. ACS Chem. Neurosci. [Internet]. 2015 [cited 2015 Aug 20];6:16–26. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25491156

18. Evans SJ, Choudary P V, Vawter MP, Li J, Meador-Woodruff JH, Lopez JF, et al. DNA microarray analysis of functionally discrete human brain regions reveals divergent transcriptional profiles. Neurobiol. Dis. [Internet]. 2003 [cited 2015 Apr 18];14:240–50.

Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3098567&tool=pmcentrez&rendertype=abstract

19. Li JZ, Vawter MP, Walsh DM, Tomita H, Evans SJ, Choudary P V, et al. Systematic changes in gene expression in postmortem human brains associated with tissue pH and terminal medical conditions. Hum. Mol. Genet. [Internet]. 2004 [cited 2015 Apr 18];13:609–16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14734628

20. Jones EG, Hendry SH, Liu XB, Hodgins S, Potkin SG, Tourtellotte WW. A method for fixation of previously fresh-frozen human adult and fetal brains that preserves histological quality and immunoreactivity. J. Neurosci. Methods [Internet]. 1992 [cited 2017 Feb 4];44:133–44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1282187

21. Johnston NL, Cervenak J, Shore AD, Torrey EF, Yolken RH, Cerevnak J. Multivariate analysis of RNA levels from postmortem human brains as measured by three different methods of RT-PCR. Stanley Neuropathology Consortium. J. Neurosci. Methods [Internet]. 1997 [cited 2017 Feb 4];77:83–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9402561

22. Gertz J, Varley KE, Davis NS, Baas BJ, Goryshin IY, Vaidyanathan R, et al. Transposase mediated construction of RNA-seq libraries. Genome Res. 2012;22:134–41.

23. Alonso A, Lasseigne BN, Williams K, Nielsen J, Ramaker RC, Hardigan AA, et al. aRNApipe: A balanced, efficient and distributed pipeline for processing RNA-seq data in high performance computing environments. Bioinformatics [Internet]. 2017 [cited 2017 Feb 3];btx023. Available from:

http://bioinformatics.oxfordjournals.org/lookup/doi/10.1093/bioinformatics/btx023

24. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics [Internet]. 2013 [cited 2017 Feb 3];29:15–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23104886

25. Kim JH, Karnovsky A, Mahavisno V, Weymouth T, Pande M, Dolinoy DC, et al. LRpath analysis reveals common pathways dysregulated via DNA methylation across cancer types. BMC Genomics [Internet]. 2012 [cited 2015 Aug 20];13:526. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3505188&tool=pmcentrez&rendertype=abstract

26. Isserlin R, Merico D, Voisin V, Bader GD. Enrichment Map - a Cytoscape app to visualize and explore OMICs pathway enrichment results. F1000Research [Internet]. 2014 [cited 2015 Aug 20];3:141. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4103489&tool=pmcentrez&rendertype=abstract

27. Darmanis S, Sloan S a., Zhang Y, Enge M, Caneda C, Shuer LM, et al. A survey of human brain transcriptome diversity at the single cell level. Proc. Natl. Acad. Sci. 2015;201507125.

28. Zhang Y, Sloan SA, Clarke LE, Caneda C, Plaza CA, Blumenthal PD, et al. Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse. Neuron [Internet]. 2015 [cited 2015 Dec 16];89:37–53. Available from: http://www.sciencedirect.com/science/article/pii/S0896627315010193

29. Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O'Keeffe S, et al. An RNA-Sequencing Transcriptome and Splicing Database of Glia, Neurons, and Vascular Cells of the Cerebral Cortex. J. Neurosci. [Internet]. 2014 [cited 2014 Sep 5];34:11929–47. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4152602&tool=pmcentrez&rendertype=abstract

30. Dunn WB, Broadhurst D, Begley P, Zelena E, Francis-McIntyre S, Anderson N, et al. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat. Protoc. [Internet]. 2011 [cited 2015 Dec 28];6:1060–83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21720319

31. Hummel J, Strehmel N, Selbig J, Walther D, Kopka J. Decision tree supported substructure prediction of metabolites from GC-MS profiles. Metabolomics [Internet]. 2010 [cited 2016 Feb 3];6:322–33. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2874469&tool=pmcentrez&rendertype=abstract

32. Castillo S, Mattila I, Miettinen J, Orešič M, Hyötyläinen T. Data analysis tool for comprehensive two-dimensional gas chromatography/time-of-flight mass spectrometry. Anal. Chem. [Internet]. 2011 [cited 2015 Aug 24];83:3058–67. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21434611

33. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette M a, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A. [Internet]. 2005;102:15545–50.

Available from: http://www.ncbi.nlm.nih.gov/pubmed/16199517

34. Network and Pathway Analysis Subgroup of Psychiatric Genomics Consortium. Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nat. Neurosci. [Internet]. 2015 [cited 2017 Feb 16];18:199–209. Available from: http://www.nature.com/doifinder/10.1038/nn.3922

35. Vita A, De Peri L, Deste G, Sacchetti E. Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies. Transl. Psychiatry [Internet]. Nature Publishing Group; 2012;2:e190. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3565772&tool=pmcentrez&rendertype=abstract

36. Berretta S, Pantazopoulos H, Lange N. Neuron numbers and volume of the amygdala in subjects diagnosed with bipolar disorder or schizophrenia. Biol. Psychiatry [Internet]. 2007 [cited 2017 Feb 2];62:884–93. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0006322307003575

37. Thompson M, Weickert CS, Wyatt E, Webster MJ. Decreased glutamic acid decarboxylase(67) mRNA expression in multiple brain areas of patients with schizophrenia and mood disorders. J. Psychiatr. Res. [Internet]. 2009 [cited 2015 May 14];43:970–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19321177

38. Skelly DA, Merrihew GE, Riffle M, Connelly CF, Kerr EO, Johansson M, et al. Integrative phenomics reveals insight into the structure of phenotypic diversity in budding yeast. Genome Res. [Internet]. 2013 [cited 2015 Aug 20];23:1496–504. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3759725&tool=pmcentrez&re

ndertype=abstract

39. Kim S, Hwang Y, Webster MJ, Lee D. Differential activation of immune/inflammatory response-related co-expression modules in the hippocampus across the major psychiatric disorders. Mol. Psychiatry [Internet]. Nature Publishing Group; 2015;1–10. Available from: http://www.nature.com/doifinder/10.1038/mp.2015.79

40. Sequeira A, Morgan L, Walsh DM, Cartagena PM, Choudary P, Li J, et al. Gene expression changes in the prefrontal cortex, anterior cingulate cortex and nucleus accumbens of mood disorders subjects that committed suicide. PLoS One [Internet]. 2012 [cited 2014 Jul 15];7:e35367. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3340369&tool=pmcentrez&rendertype=abstract

41. Sorenson SB. Gender disparities in injury mortality: Consistent, persistent, and larger than you'd think. Am. J. Public Health. 2011;101:353–8.

42. Aubin H-J, Rollema H, Svensson TH, Winterer G. Smoking, quitting, and psychiatric disease: A review. Neurosci. Biobehav. Rev. [Internet]. 2012 [cited 2017 Feb 3];36:271–84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21723317

43. Wolock SL, Yates A, Petrill SA, Bohland JW, Blair C, Li N, et al. Gene × smoking interactions on human brain gene expression: finding common mechanisms in adolescents and adults. J. Child Psychol. Psychiatry. [Internet]. NIH Public Access; 2013 [cited 2017 Feb 3];54:1109–19. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23909413

44. Weissman DH, Gopalakrishnan a., Hazlett CJ, Woldorff MG. Dorsal anterior

cingulate cortex resolves conflict from distracting stimuli by boosting attention toward relevant events. Cereb. Cortex. 2005;15:229–37.

45. Paus T. Primate anterior cingulate cortex: where motor control, drive and cognition interface. Nat. Rev. Neurosci. 2001;2:417–24.

46. Carter CS, Braver TS, Barch DM, Botvinick MM, Noll D, Cohen JD. Anterior cingulate cortex, error detection, and the online monitoring of performance. Science. 1998;280:747–9.

47. Woo T-UW, Kim AM, Viscidi E. Disease-specific alterations in glutamatergic neurotransmission on inhibitory interneurons in the prefrontal cortex in schizophrenia. Brain Res. [Internet]. 2008 [cited 2015 May 27];1218:267–77. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2665281&tool=pmcentrez&rendertype=abstract

48. Yamada K, Gerber DJ, Iwayama Y, Ohnishi T, Ohba H, Toyota T, et al. Genetic analysis of the calcineurin pathway identifies members of the EGR gene family, specifically EGR3, as potential susceptibility candidates in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. [Internet]. 2007 [cited 2015 Aug 19];104:2815–20. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1815264&tool=pmcentrez&rendertype=abstract

49. Pérez-Santiago J, Diez-Alarcia R, Callado LF, Zhang JX, Chana G, White CH, et al. A combined analysis of microarray gene expression studies of the human prefrontal cortex identifies genes implicated in schizophrenia. J. Psychiatr. Res. [Internet]. Elsevier; 2012 [cited 2017 Feb 3];46:1464–74. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22954356

50. Zhang L, Cho J, Ptak D, Leung YF. The Role of egr1 in Early Zebrafish Retinogenesis. PLoS One. 2013;8:1–11.

51. Baumgärtel K, Genoux D, Welzl H, Tweedie-Cullen RY, Koshibu K, Livingstone-Zatchej M, et al. Control of the establishment of aversive memory by calcineurin and Zif268. Nat. Neurosci. [Internet]. 2008 [cited 2017 Feb 3];11:572–8. Available from: http://www.nature.com/doifinder/10.1038/nn.2113

52. Bruins Slot LA, Lestienne F, Grevoz-Barret C, Newman-Tancredi A, Cussac D. F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum. Eur. J. Pharmacol. [Internet]. 2009 [cited 2017 Feb 3];620:27–35. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0014299909006906

53. Xu Y, Yue W, Shugart YY, Li S, Cai L, Li Q, et al. Exploring transcription factors-microRNAs co-regulation networks in schizophrenia. Schizophr. Bull. 2016;42:1037–45.

54. Koldamova R, Schug J, Lefterova M, Cronican AA, Fitz NF, Davenport FA, et al. Genome-wide approaches reveal EGR1-controlled regulatory networks associated with neurodegeneration. Neurobiol. Dis. [Internet]. 2014 [cited 2017 Feb 26];63:107–14. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0969996113003173

55. Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dwyer S, Gormley P, et al. De novo mutations in schizophrenia implicate synaptic networks. Nature [Internet]. 2014 [cited 2014 Jul 10];506:179–84. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4237002&tool=pmcentrez&rendertype=abstract

56. Fromer M, Roussos P, Sieberts SK, Johnson JS, Kavanagh DH, Perumal TM, et al. Gene expression elucidates functional impact of polygenic risk for schizophrenia. Nat. Neurosci. [Internet]. 2016;19:1442–53. Available from: http://www.nature.com/doifinder/10.1038/nn.4399

57. Guillozet-Bongaarts AL, Hyde TM, Dalley RA, Hawrylycz MJ, Henry A, Hof PR, et al. Altered gene expression in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol. Psychiatry [Internet]. Nature Publishing Group; 2014 [cited 2017 Feb 3];19:478–85. Available from: http://www.nature.com/doifinder/10.1038/mp.2013.30

## Figure Legends

**Figure 1**. (A) Histograms of case vs. control differential expression (DESeq2 *P*-values) for SZ (red), BPD (blue), and MDD (green) in each brain region assayed. (B) Pairwise spearman correlations of $\log_2$ fold gene expression changes between each disorder and CTL in each brain region. Circle sizes are scaled to reflect Spearman correlations. (C) Venn diagram showing overlap of genes differentially expressed between SZ (red), BPD (blue), MDD (green) vs. CTL at a p-value<0.05. (D) $\text{Log}_2$ fold expression change correlation of 87 genes with FDR<0.05 comparing SZ and CTL (AnCg) in the Pritzker dataset with the SNCID dataset (Spearman coefficient=0.812, p-value<0.0001). Transcripts differentially expressed at an FDR<0.05 in both cohorts are identified with red circles. (E) Hierarchical clustering 27 SZ and 26 CTL tissues in the SNCID dataset using variance-stabilized expression of 87 significant genes between SZ and CTL in the AnCg identified by DESeq2 (FDR<0.05) in the Pritzker dataset. CTL (black), SZ (red), lowly expressed genes (blue pixels), highly expressed genes (yellow pixels).

**Figure 2.** (A) Boxplots indicating relative expression of *EGR1* in the AnCg of SZ (red), BPD (blue), MDD (green), and CTL (gray). (B) Correlation plot comparing RNA-seq measured expression level of *EGR1* to qPCR measured expression in 10 SZ (red) and 10 CTL (black) patients. (C) Wilcoxon *P*-values resulting from comparing the degree of differential expression (based on DESeq2 *P*-values) of genes whose TSSs neighbor *EGR1* binding sites to genes whose TSSs are greater than a range of distance thresholds.

**Figure 3**. Boxplots indicating neuron- (A) and astrocyte- (B) specific expression indices in the AnCg for SZ (red), BPD (blue), MDD (green), and CTL (gray) individuals. (C) Correlation plot comparing the $\log_2$ expression fold change between SZ and CTL patients in the AnCg and the $\log_2$ expression fold change between dissected neurons and all other dissected brain cell types (astrocytes, oligodendrocytes, endothelial cells, and microglia).

**Figure 4.** Hierarchical clustering of (A) 25 metabolites that differ most between SZ (red) and CTL (black) indibiduals, and (B) 25 metabolites that differ most between BPD (blue) and CTL (black) individuals. (C) Boxplots indicating relative expression of GAD1 and GAD2 enzymes in the AnCg of SZ (red) and CTL (gray) patients. (D) Correlation plot comparing average GAD1 and GAD2 expression and the GABA/Glutamate metabolite level ratio in the AnCg of SZ (red) and CTL (black) individuals.

## Supplementary Figure Legends

**Figure S1.** A) Principal components analysis of all 281 brain tissues. AnCg (red squares), DLPFC (blue triangles), nAcc (green circles). B) Principal components analysis of all 281 brain tissues. CTL (gray squares), BPD (blue triangles), MDD (green

circles), SZ (red triangles). (C) Principal components analysis of all 281 brain tissues after correcting RNA-seq data for alignment quality. CTL (gray squares), BPD (blue triangles), MDD (green circles), SZ (red triangles).

**Figure S2.** Principal components analysis of all AnCg (A,D), DLPFC (B,E), and nAcc (C,F) samples before and after correction for RNA-seq alignment quality. (G-I) PC1 values in CTL (gray), BPD (blue), MDD (green), and SZ (red) patients pre- and post-RNA-seq alignment quality correction in the AnCg (G), DLPFC (H), and nAcc (I).

**Figure S3**. GO-term analysis for transcripts differentially expressed in SZ vs. CTL in AnCg (FDR<0.05). Up-regulation (red circles), down-regulation (blue circles).

**Figure S4.** Examination of cell-type specific index in purified (A) neuron, (B) astrocytes, (C) oligodendrocytes, (D) microglia, and (E) endothelial cells from brain tissue. (F) Neuron and astrocyte indices are capable of predicting *in silico* mixed cell-type proportions. (G) Mean values with standard deviation for predictions of indices generated on 10,000 randomly sampled, null transcript sets. (H, I) Histogram of mean squared error of null index cell type proportion predictions for mixed neuron and astrocyte transcriptomes with Darmanis et al. transcript performance indicated in red.

**Figure S5.** Boxplots of endothelial (A), microglia (B), and oligodendrocyte (C) cell type indices in SZ (red), BPD (blue), MDD (green), and CTL (gray) individuals.

**Figure S6.** Hierarchical clustering of 25 metabolites with levels that differ most between MDD (green) and CTL (black) individuals.

**Figure S7.** Integrated KEGG pathway analysis of metabolite and RNAseq differences between SZ and CTL patients. Top 10 pathways shown for metabolite, transcript and combined analysis.


A
AnCg
DLPFC
nAcc
SZ
BPD
MDD
Frequency
0
4000
0.0
0.4
0.8
p-Value
B
AnCg
DLPFC
nAcc
SZ
BPD
MDD
SZ AnCg
BPD AnCg
MDD AnCg
SZ DLPFC
BPD DLPFC
MDD DLPFC
SZ nAcc
BPD nAcc
MDD nAcc
1
0.8
0.6
0.4
0.2
0.0
−0.2
−0.4
−0.6
−0.8
−1
C
SZ
BPD
MDD
3881
949
1007
71
177
72
1560
D
FDR<0.05 in both cohorts
SCNID Log2 Fold Change
Pritzker Log2 Fold Change
E
SZ
CTL
Scaled Expression Level
Genes
Patients


A
Variance Stabilized Counts
13.0
12.5
12.0
11.5
11.0
10.5
10.0
SZ
BPD
MDD
CTL
B
SZ
CTL
qPCR Expression (−deltaCT)
4
5
6
7
rho = −0.92
10
11
12
13
14
RNAseq Expression (Variance Stabilized Counts)
C
Wilcox P−Value (−log10)
0
2
4
6
8
10
12
14
P=0.05
0
10000
30000
50000
Distance of TSS to EGR1 Binding Site


A
Neuron Specific Expression
Neuron Index
0.4
0.0
−0.4
−0.8
*
*
SZ
BPD
MDD
CTL
*Wilcox P<0.05, **Wilcox P<0.01
B
Astrocyte Specific Expression
Astrocyte Index
1.0
0.5
0.0
-0.5
−1.0
**
*
SZ
BPD
MDD
CTL
*Wilcox P<0.05, **Wilcox P<0.01
C
rho = -0.5
Log2 Fold Enrichment in Neurons
5
0
−5
−1.0
−0.5
0.0
0.5
1.0
SZ v. CTL Log2 Fold Change
Number of Points
1000
100
10
1


A
SZ
CTL
Scaled Metabolite Level
4
2
0
−2
Metabolites
Patients
B
BPD
CTL
Scaled Metabolite Level
4
2
0
−2
Metabolites
Patients
C
DESeq2 Variance Stabilized Counts
13
12
11
10
***
***
GAD1
GAD2
*** DESeq2 P-value < 0.001, FDR<0.077
D
SZ
CTL
rho = 0.413
GABA/Glutamate Ratio
1.8
1.4
1.0
0.6
10.5
11.5
12.5
Average GAD Expression


A
Colored by Brain Region
AnCg
DLPFC
nAcc
PC2 (12.41%)
PC1 (21.78%)
B
Colored by Disorder
CTL
BPD
MDD
SZ
PC2 (12.41%)
PC1 (21.78%)
C
Corrected for RNA Quality
CTL
BPD
MDD
SZ
PC2 (10.81%)
PC1 (18.46%)


A
AnCg
PC2 (8.39%)
PC1 (20.6%)
B
DLPFC
PC2 (8.47%)
PC1 (15.41%)
C
nAcc
PC2 (9.28%)
PC1 (22.11%)
D
AnCg
PC2 (9.28%)
PC1 (12.72%)
E
DLPFC
PC2 (8.66%)
PC1 (10.46%)
F
nAcc
PC2 (8.86%)
PC1 (18.69%)
CTL
BPD
SZ
MDD
G
AnCg
PC1
H
DLPFC
PC1
I
nAcc
PC1
Pre-QC Correction
Post-QC Correction
*Wilcox P-Value < 0.05


Translation
Metabolism
cAMP synthesis
Immune response
Neurotransmitter Transport
Synapse function
Regulation of cell-cell communication
Nucleotide binding
Protein metabolism
Ion transport
Response to Stimulus
Nucleic acid metabolism
Differentiation
Organismal development
Secretion
Calcium signaling
Chemotaxis


A
Neuron Index
Astrocyte
Neuron
Oligodendrocyte
Microglia
Endothelial
Dissected Cell Type
B
Astrocyte Index
Dissected Cell Type
C
Oligodendrocyte Index
Dissected Cell Type
D
Microglia Index
Dissected Cell Type
E
Endothelial Index
Dissected Cell Type
F
Deconvolution of in silico mixing
Predicted Cell Proportion
Neuron
Astrocyte
Astrocyte: 1.0 0.8 0.6 0.4 0.2 0.0
Neuron: 0.0 0.2 0.4 0.6 0.8 1.0
Actual Cell Proportion
G
Performance of Null Models
Predicted Cell Proportion
Neuron
Astrocyte
Neuron: 1.0 0.8 0.6 0.4 0.2 0.0
Astrocyte: 0.0 0.2 0.4 0.6 0.8 1.0
Actual Cell Proportion
H
Permutation Test of Neuron Prediction
Frequency
p = 0.0006
Darmanis et al. Performance
Neg. Log10 Mean Squared Error
I
Permutation Test of Astrocyte Prediction
Frequency
p = 0.0001
Darmanis et al. Performance
Neg. Log10 Mean Squared Error


A
Endothelial Index
−1.5
−0.5
0.0
0.5
1.0
1.5
SZ
BPD
MDD
CTL
B
Microglia Index
−1
0
1
2
SZ
BPD
MDD
CTL
C
Oligodendrocyte Index
−2.0
−1.0
0.0
0.5
1.0
1.5
SZ
BPD
MDD
CTL


MDD
CTL
Scaled Metabolite Level
4
2
0
−2


Combined RNAseq and Metabolomics Pathway Enrichment
Neg. Log p-value
0
1
2
3
4
5
6
Bonferroni Corrected 0.05
RNAseq Pathway Enrichment
Neg. Log p-value
0
1
2
3
4
5
6
7
Metabolite Pathway Enrichment
Neg. Log p-value
0.0
0.2
0.4
0.6
0.8
1.0
Glutamatergic Synapse
Endocannabinoid Signaling
Long-term Potentiation
Serotonergic Synapse
Cholinergic Synapse
Neuroactive Ligand-Receptor
GABAergic Synapse
cGMP-PKG Signaling
Adrenergic Signaling
Branched Chain AA Degradatoin